Grace Therapeutics (GRCE) Net Shares Issued and Repurchased (2019 - 2026)

Grace Therapeutics has disclosed Net Shares Issued and Repurchased across 7 years of filings, most recently posting $431530.0 for Q1 2026.

• In Q1 2026, Net Shares Issued and Repurchased rose 102.47% year-over-year to $431530.0; the TTM figure through Mar 2026 stood at $431530.0 (up 102.47% YoY), while the FY2026 annual figure was $431530.0, up 102.47% from the prior year.
• Net Shares Issued and Repurchased came in at $431530.0 for Q1 2026 at Grace Therapeutics, up from $391530.0 in the prior quarter.
• In the past five years, Net Shares Issued and Repurchased ranged from a high of $2.1 million in Q1 2022 to a low of $198130.0 in Q2 2024.
• Average Net Shares Issued and Repurchased over 5 years is $775205.7, with a median of $431530.0 recorded in 2026.
• Year-over-year, Net Shares Issued and Repurchased jumped 15691.12% in 2022 and sank 78.79% in 2023.
• Over 5 years, Net Shares Issued and Repurchased stood at $1.3 million in 2022, then slumped by 78.79% to $267797.0 in 2023, then dropped by 26.01% to $198130.0 in 2024, then soared by 97.61% to $391530.0 in 2025, then grew by 10.22% to $431530.0 in 2026.
• Per Business Quant data, the three most recent Net Shares Issued and Repurchased figures were $431530.0 in Q1 2026, $391530.0 in Q2 2025, and $213130.0 in Q1 2025.